EMERCell Receives Strategic Investment from Onward Therapeutics
Summary
EMERCell SAS, a Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells, received a strategic investment from Onward Therapeutics. Onward will assist EMERCell to scale up their patented process of activation and amplification of allogeneic NK cells and to conduct clinical investigations. “Through its capital investment in EMERCell, Onward will have access to a proprietary technology to produce highly activated NK cells. The company, which collaborates with numerous industrial and academic partners, has received the support of the Occitanie Region (ADI) and Bpifrance and has obtained a FUI (financing). A member of Eurobiomed, EMERCell is located at the IRMB (Institute of Regenerative Medicine and Biotherapies) at the Saint-Eloi University Hospital Center, Montpellier, France.